Crescent Biopharma
CBIO
80 hedge funds and large institutions have $535M invested in Crescent Biopharma in 2017 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 9 closing their positions.
244% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 9
38% more funds holding
Funds holding: 58 → 80 (+22)
32% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 19
29% more capital invested
Capital invested by funds: $416M → $535M (+$119M)
0.02% more ownership
Funds ownership: 0.91% → 0.93% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
46% less call options, than puts
Call options by funds: $2.14M | Put options by funds: $3.96M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$18M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$9.48M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
+$8.98M |
| 4 |
Axa
Paris,
France
|
+$6.76M |
| 5 |
Janus Henderson Group
London,
|
+$6.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$36.1M |
| 2 |
Millennium Management
New York
|
-$8.88M |
| 3 |
O
OrbiMed
New York
|
-$4.72M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.59M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.65M |
CBIO Hedge Fund Activity: Q4 2017 in Review
80 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q4 2017, worth a combined $535M — up 29% from $416M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CBIO positions and 9 closed out — a net gain of 22 holders — while 25 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $18M. The largest seller was BVF Inc, cutting an estimated $36.1M.
- 80 institutional investors held Crescent Biopharma (CBIO) as of Q4 2017, up from 58 in Q3 2017.
- Funds reported $535M of Crescent Biopharma stock for Q4 2017, up 29% quarter-over-quarter.
- 31 funds opened new Crescent Biopharma positions in Q4 2017 and 9 closed out, a net change of +22 holders.
- The largest Crescent Biopharma buyer in Q4 2017 was Fidelity Investments, an estimated $18M added.
- The largest Crescent Biopharma seller in Q4 2017 was BVF Inc, an estimated $36.1M sold.
Based on aggregated 13F filings for Q4 2017.